Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Antigen-specific Immunoprofiling in a Patient With Eisenmenger Syndrome, Treated Tuberculosis, and Atypical Non-tubercular Mycobacteria (NTM) Isolation Prior to Bilateral Lung Transplant
Lynn-Green, E., Pathakumari, Balaji , Keulen, Virginia P. Van , Peikert, Tobias, Pennington, Kelly M. , Escalante, Patricio , Gutierrez, L.E.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7894-A7894

10.1164/ajrccm.2025.211.abstracts.a7894 Get It

Abstract Non-tubercular mycobacteria (NTM) present a serious challenge in managing lung transplant candidates and recipients. Pretransplant NTM isolation has been associated with post-transplant NTM infection and significantly increased mortality risk. Strategies for managing pre-transplant NTM isolation vary widely in clinical practice. We present a 35-year-old lung transplant candidate from a tuberculosis-endemic country with severe pulmonary hypertension and Eisenmenger Syndrome due to unrepaired atrial septal defect, who underwent bilateral lung transplantation. Two years prior to transplant, she was successfully treated for pulmonary tuberculosis with six months of an unknown regimen in her home country. After moving to the U.S., she received M. tuberculosis (MTB) clearance from her state tuberculosis board, with three negative sputum samples six months prior to transplant. During her transplant evaluation, multi-drug-resistant M. fortuitum complex was isolated from one mycobacterial sputum culture. There was no clinical or radiographic evidence of active lung infection, and no targeted therapies were added. Standard peri-transplant antibiotics (vancomycin, cefepime, and caspofungin) were given. The patient received basilixamab for induction immunosuppression, and tacrolimus, mycophenolate mofetil, and prednisone for maintenance immunosuppression. Explant pathology showed necrotizing granuloma in the right upper lobe with acid-fast bacilli (AFB). The differential diagnosis included non-viable MTB, viable MTB despite prior clearance, or M. fortuitum. Three bronchoscopy washings were obtained in the first week post-transplant and returned negative for MTB by PCR, AFB stain, and culture. In collaboration with the Mycobacteriology laboratory, broad-range PCR testing was performed on the formalin-fixed paraffin-embedded samples from the explanted right lung, which was positive for MTB complex DNA. In total, the patient completed six sputum samples within the year pre-transplant and six respiratory samples within a month post-transplant, all of which returned negative for MTB by PCR, AFB stain, and culture. Blood flow cytometric (FC) immunoprofiling with mycobacterial antigens and controls was conducted (Escalante et al. 2015). The patient's FC antigen-specific activated T-cell profiling was consistent with a reduced risk of latent TB infection (FC CD4+ CD25+CD134+ T-cells (RD1-peptides-nil) = 0.19%). T-cell reactivity to MTB300 and PPD antigens suggested prior MTB, NTM, and/or BCG vaccination exposures. She progressed well without any preventive therapy for LTBI. FC immunoprofiling one year after transplantation showed similar results. She continues to have good pulmonary function and quality of life in her second-year post-transplant without evidence of NTM or MTB infection. Escalante P, et al. Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2015;192(5):605-17. PMCID: PMC4595688.
The Role of Senolytics in Reducing Senescence Induced by Cannabinoids and Nicotine in Prenatal Human Lung
Alam, I. El, Belgacemi, R., Glass, I., Zana-Taeib, Elodie, Boyer, L., Danopoulos, S., Alam, D. Al, Glass, I., Zana‐Taïeb, Elodie , Boyer, L., Rehan, Virender Kumar , Prakash, Y. S. , Pabelick, Christina M. , Alam, D. Al

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7706-A7706

10.1164/ajrccm.2025.211.abstracts.a7706 Get It

Abstract Rationale: Tandem exposure to cannabinoids and nicotine during pregnancy poses significant risks to fetal development and health including low birth weight, preterm birth, and perinatal death. However, the effect of co-exposure with the most prominent cannabinoids found in Cannabis sativa (Trans-Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) alongside nicotine on fetal lung development is not well understood. This study aims to investigate the combinatorial impact of CBD, THC, and nicotine, on human lung development through investigating cellular senescence and the potential role of senolytics in alleviating these effects.Methods: Human fetal lung explants from 10 to 16 weeks gestation were cultured on air-liquid interface and treated with various concentrations of nicotine (1µM), CBD, and THC (5µM, or 2.5µM each when used in combination), for 72 hours. To assess the effect of senolytics, the explants were also treated for 48 hours with a combination of CBD, THC, and nicotine. Subsequently, senolytics, Dasatinib (D, 250nM) and Quercetin (Q, 375nM), were added or not for an additional 24 hours. After the 72-hour treatment, explants were collected and either fixed for immunofluorescence staining (IF) analyses or used for RNA extraction and quantitative reverse transcription PCR (qRT-PCR). Additionally, the supernatants were used to evaluate the expression of the senescence-associated secretory phenotype (SASP), conducted by Eve Technologies Corporation-Canada. This study used Luminex xMAP technology for multiplexed quantification of 96 Human cytokines, chemokines, and growth factors.Results: Our results demonstrated that co-exposure to CBD, THC, and nicotine increases the expression of the senescence markers CDKN1A (0.1163±0.02384, p=0.0094, n=8) and CDKN2A (0.005793±0.002157, p=0.0516, n=8) encoding P21 and P16 respectively. Moreover, the IF staining showed increased expression of the DNA damage marker ɣH2A.X following treatment with CBD+THC+nicotine (7.375±2.154% vs 2.245±0.8329%, p=0.0604, n=6). Furthermore, the lung explants treated with cannabinoids and nicotine released cytokines and chemokines involved in immune responses and inflammation among others IL-6, IL-8, M-CSF, MCP-3, MIP-1β, TNFα, MIP-3β, and TSLP (p<0.05). The addition of D+Q reduced SASP secretion and showed a decreasing trend in expression of the senescence genes CDKN1A and CDKN2A compared to the triple treatment.Conclusion: Taken together, our results showed that the combinatorial exposure to CBD, THC, and nicotine increases senescence, DNA damage, and the senescence-associated secretory phenotypes (SASP) secretion. The use of senolytics (D+Q) may prove to be a promising therapeutic option, alleviating several of the negative effects induced by the different substances.
Harmonized Assessment and Quality Control of Quantitative Measures of Lung Structure on Pre-pandemic Cardiac and Lung Computed Tomography (CT) Scans for Large-scale Investigation of Risk of Long COVID-19: The Collaborative Cohort of Cohorts for COVID-19 Re
Naik, Seema , Smith, B.M. , Cheng, T.-K., Lynch, David A. , Matsushita, Kunihiro , O'Driscoll, O., Ortega, Victor E. , Washko, George R. , Laine, Andrew F. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Naik, S., Allen, Norrina B. , Balte, Pallavi , Blaha, Michael Joseph , Budoff, Matthew J. , Carr, J. Jeffrey , Carson, April P. , Cheng, T.-K., Estépar, Raúl San Jośe , Hoffman, Eric A. , Humphries, Stephen M. , Kanaya, Alka M , Kandula, Namratha R. , O’Connor, George T. , Pottinger, Tess D. , Schwartz, David A. , Wenzel, Sally E. , Xanthakis, Vanessa , Angelini, Elsa D. , Barr, R. Graham

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7658-A7658

10.1164/ajrccm.2025.211.abstracts.a7658 Get It

Abstract RATIONALE: Susceptibility to severe COVID-19 and long COVID may be influenced by pre-existing lung structure. ECG-gated, non-contrast cardiac CT scans, originally acquired for assessing coronary artery calcium, are available in multiple longitudinal cohort studies and have been previously validated against lung CT scans for densitometry; however, protocol variation across cohorts may hinder direct comparison. To address this, we developed a quality control (QC) rubric to grade cardiac CT scans for standardized quantitative lung measures across cohorts. METHODS: C4R assessed SARS-CoV-2 infection and outcomes in 14 NHLBI cohorts, of which 10 (six community-based and four longitudinal case-control studies) included CT scans (12,459 participants with lung and 13,752 with cardiac CTs). Logic rules were applied to categorize scans (Table): Grade “A-B” scans had 2-3.5mm slice thickness, at least 20 axial slices, no lung cropping in axial view and lung and airway volumes greater than the cohort-specific 1st percentile. “C-D” scans had one lung obscured by cropping around the heart, so quantitative measures were restricted to the lung in complete view. “F-H” scans were deemed unusable, suffering from low slice count (<20), severe image cropping, low lung or airway volumes (< 1st%ile). Visual inspection was performed on a sample from each category to ensure accuracy. Percent of lung voxels in low attenuation areas < -950 HU (LAA950), high attenuation areas (-600 to -250 HU, HAA) and 15th percentile HU value (perc15) were measured. Within-participant variability was quantified using the intraclass correlation coefficient (ICC). RESULTS: We performed QC on cardiac CT scans from an initial sample of 6,275 participants from three C4R cohorts (ARIC, CARDIA, MASALA), imaged with GE or Siemens scanners. Of these, 5,125 (81.7%) were graded “A-B”, 496 (7.9%) were “C-D” and 654 (10.4%) were “F-H”. The percentage of “F-H” scans varied widely across cohorts [<1% to 26%] due to image cropping. Among the 5,621 cardiac CT scans graded A-D, the mean±SD for LAA950, HAA and perc15 respectively were 1.1±2.1%, 7.2±4.7% and -887±33 HU. Repeated imaging was available for 107 participants (time interval 5.1±0.7y). For paired scans in grades A-B (n=101/107), the within-participant correlation for LAA950, HAA and perc15 were 0.91, 0.38 and 0.74 respectively. CONCLUSION: Initial application of QC to cardiac CT scans identified scans with high reproducibility, with the aim to provide valid quantitative lung metrics on over 20,000 highly characterized participants in C4R.
Innate Immune Inhibition of Collagenolytic Protease Cathepsin K May Play a Role in Fibrosis Progression
Meridew, Jeffrey A., Choi, Kukbin , Tschumperlin, Daniel J. , Link, Patrick A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7638-A7638

10.1164/ajrccm.2025.211.abstracts.a7638 Get It

Abstract Rationale Extracellular matrix (ECM) accumulation results from an imbalance between ECM deposition and degradation, due to persistently increased ECM synthesis or reduced resorption. Fibroblasts, as key regulators of ECM homeostasis in both health and disease, are essential targets to rebalance ECM turnover. Recent findings indicate that fibroblasts are regulated by immune cells, which can influence ECM deposition. Specifically, myeloperoxidase (MPO), an enzyme produced by neutrophils, has been shown to enhance fibroblast-driven ECM accumulation in various diseases. In patients with radiographic Interstitial Lung Disease (ILD), elevated MPO levels have been correlated with reduced lung capacity (Cantin et al., 1987), while recent studies report increased MPO levels in the bronchoalveolar lavage fluid of ILD patients (Ngo et al., EJROR 2024). Additionally, MPO and related immune dysregulation proteins are found in fibrotic alveoli in Idiopathic Pulmonary Fibrosis (IPF) (Herrera et al., JCI Insight 2022). These findings suggest an association between MPO and lung fibrosis, yet it remains uncertain whether MPO directly influences ECM accumulation in fibrotic progression. Methods Patient tissue and serum samples were collected with consent, and MPO levels were quantified using ELISA and immunofluorescence techniques. Biochemical assays were performed using MPO isolated from human leukocytes, recombinant cathepsin K, and hydrogen peroxide to investigate whether MPO influences cathepsin K activity. Precision cut lung slices (PCLS) were prepared from untreated C57BL/6 mice and treated with transforming growth factor-beta (TGFβ) and/or MPO for four days, with cathepsin K activity assessed using fluorescence assays. Additionally, MPO-knockout and wild-type mice received intratracheal bleomycin, and after 14 days, cathepsin K activity was quantified via in vivo imaging. Collagen content, as an indicator of fibrosis, was measured by quantifying hydroxyproline in harvested lung tissue. Results/Discussion/Conclusion Increased MPO levels were observed in immunofluorescent-stained samples (57%; 4/7) and serum samples (30%; 3/10) from IPF patients. Biochemical assays demonstrated that physiological levels of MPO (0.2 µg/ml) combined with H2O2 reduced recombinant cathepsin K activity by 85%. In PCLS treated with MPO, cathepsin K activity decreased by 50% with or without TGFβ. After bleomycin treatment, wild-type mice showed reduced cathepsin K activity, while MPO-knockout mice maintained activity levels. Both survival and weight loss were similar between wild-type and MPO-knockout mice; however, collagen content was significantly higher in wild-type mice, whereas MPO-knockout mice were protected from bleomycin-induced collagen accumulation. These findings suggest that MPO contributes to ECM accumulation in lung fibrosis, potentially through inhibition of collagenolytic enzymes such as cathepsin K.
Addition of Patient-Reported Outcomes Improves Discrimination of Survival Prediction Models in Pulmonary Arterial Hypertension
Balasubramanian, A. , Simpson, C., Hassoun, P.M., Larive, Brett , Rosenzweig, E.B., Hill, Nicholas S. , Erzurum, S.C., Mathai, S.C., Group, PVDOMICS Study, Mathai, Stephen C. , Balasubramanian, Aparna , Mathai, Stephen C , Balasubramanian, Aparna , DuBrock, Hilary M. , Lammi, Matthew R. , Kolb, Todd M. , Hassoun, P.M., Horn, Evelyn M. , Hemnes, Anna R. , Leopold, Jane A. , Rischard, Franz , Frantz, Robert P.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7611-A7611

10.1164/ajrccm.2025.211.abstracts.a7611 Get It

Abstract Rationale: The 7th World Symposium on Pulmonary Hypertension highlighted the importance of patient-reported outcomes in clinical assessment of pulmonary arterial hypertension (PAH). Patient-reported outcomes, such as health-related quality of life (HRQOL), have been associated with morbidity and mortality in PAH, but the added value of HRQOL measures to validated risk prediction models remains unknown. Methods: Adults with RHC-proven PAH from the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) Study, a multi-center observational study, were included in this study. The Pulmonary Hypertension Association Registry (PHAR) was used as a validation cohort. HRQOL was measured using the emPHasis-10 score, where higher scores reflect worse HRQOL. Noninvasive risk assessment was measured by REVEAL Lite 2 risk score, categorized into 3-strata. Cox proportional hazard models were used to model survival evaluating the interaction between risk strata and HRQOL scores, adjusting for age, sex, and incident diagnosis. Harrell's C-statistics were calculated to compare discriminative performance. Results: From the PVDOMICS and PHAR cohorts, 265 and 2671 individuals with PAH and complete emPHasis-10 and REVEAL Lite 2 scores were included. Both cohorts had similar demographics, with an average age of 52±13 and 56±16 years, 75% and 72% female, 81% and 75% White, in the PVDOMICS and PHAR cohorts respectively. Over 87% of PVDOMICS were prevalent cases of PAH, while in the PHAR half were incident. Most individuals (62%) in PVDOMICS were REVEAL Lite 2 low risk, with 16% intermediate and 22% high risk; by contrast, in PHAR 33% were low, 29% intermediate, and 38% high risk. REVEAL Lite 2 scores demonstrated weak to moderate correlation with emPHasis-10 scores in both cohorts (PVDOMICS r=0.48 p<0.001; PHAR r=0.33 p<0.001). Notably, the full range of emPHasis-10 scores were observed in the low-risk individuals across both cohorts. In the PVDOMICS adjusted Cox models, higher emPHasis-10 scores predicted poorer survival (p=0.047) particularly among low-risk individuals (interaction versus high-risk group p=0.08). Similar adjusted models in PHAR demonstrated emPHasis-10 to be a confounder (p=0.001) without significant interaction by risk strata (low vs high-risk interaction p=0.94), but the greatest change in median survival time was observed in the low-risk group (Figure 1). Addition of emPHasis-10 to REVEAL Lite 2 scores improved discrimination in predicting survival (PVDOMICS: C-statistic 0.71 vs 0.73; PHAR: C-statistic 0.67 vs 0.69). Conclusions: Across two multicenter cohorts of incident and prevalent PAH, HRQOL as measured by the emPHasis-10 score improved discrimination for survival, particularly among individuals with lower risk scores.
Hemolytic Uremic Syndrome Complicated by Transfusion-related Acute Lung Injury
Friesen, Joelle N. , Finnegan, Kyle, Merrill, Robert , Overgaard, Jens , Saha, Bibek , Daher, Darine , Finnegan, K.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7537-A7537

10.1164/ajrccm.2025.211.abstracts.a7537 Get It

Abstract Introduction: Hemolytic uremic syndrome (HUS) is especially uncommon in adults and can manifest as devasting complications including severe acute kidney injury (AKI) and microangiopathic hemolytic anemia (MAHA). Transfusion-related acute lung injury (TRALI) is a rare complication of blood product transfusion that is characterized by the rapid development of noncardiogenic pulmonary edema. We present a rare case of HUS complicated by TRALI requiring mechanical ventilation. Case Description: A 41-year-old female farmer, who occasionally drank raw cow's milk, was admitted with abdominal pain and distension, bloody diarrhea, poor appetite, decreased urine output and fatigue. She was found to have MAHA and stage 3 AKI. Imaging demonstrated pancolitis and workup revealed Shiga toxin-producing E. coli, O157:H7 serotype which was consistent with a diagnosis of HUS. Tests for DIC, TTP and atypical HUS were negative. She was not a candidate for dialysis, plasma exchange or eculizumab. With supportive measures including 3 units of packed red blood cell (pRBC), her symptoms, renal function, and bicytopenia improved and she was discharged. Two days post-discharge, she presented to the ED for unilateral vision changes, left hemiparesis, and lower extremity tremor. After negative neurological evaluation, this was attributed to encephalopathy secondary to HUS. She received 1 unit of pRBCs for a hemoglobin of 6.8. Within 3 hours of transfusion, she developed acute respiratory distress requiring intubation and ICU transfer. CT chest angiogram was negative for pulmonary embolism but demonstrated diffuse bilateral lower lobe dependent consolidations concerning for TRALI (Figure 1). After diuresis, she was able to be extubated within 48 hours with return to her respiratory and neurologic baselines soon after. Discussion: The pathophysiology of TRALI involves neutrophil sequestration and priming in the pulmonary vasculature with subsequent neutrophil activation by donor blood product factors where active infection is a known risk factor. Active HUS likely contributed to neutrophil priming through endothelial damage and systemic inflammation, predisposing this patient to TRALI. There are few reports of similar cases in the literature. TRALI can be subdivided into type I and type II; type I has no risk factors for acute respiratory distress syndrome (ARDS) while type II does. TRALI must also be distinguished from ARDS and transfusion-associated circulatory overload; these distinctions are predominantly made based on timing of respiratory symptom onset. This case highlights the importance of keeping TRALI in the differential for all patients with active or recent infection, including HUS, who develop acute-onset respiratory decompensation after transfusion.
Triple Threat: Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome Triggered by Immune Checkpoint Inhibitors in Metastatic Melanoma
Li, Song , Sen, Adrish , Rajesh, S.T., Chen, Jing , Sen, A.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7535-A7535

10.1164/ajrccm.2025.211.abstracts.a7535 Get It

Abstract Immune checkpoint inhibitor (ICI) therapy has significantly advanced cancer treatment, particularly for metastatic melanoma, but it is associated with severe, life-threatening adverse effects. A rare but critical complication is the overlap syndrome of Myositis, Myocarditis, and Myasthenia Gravis (MMM), affecting approximately 0.21% of ICI-treated solid tumor patients with an in-hospital mortality rate of up to 60%. Early recognition and management are crucial for improving outcomes. Case Presentation: A 76-year-old male with metastatic melanoma, coronary artery disease, ischemic cardiomyopathy (EF 35%), chronic kidney disease, diabetes, and chronic respiratory failure (baseline oxygen requirement of 2L) presented two weeks after starting Nivolumab and Relatlimab. He developed worsening exertional dyspnea, orthopnea, diplopia, dysarthria, and progressive proximal muscle weakness. On presentation, he was hemodynamically stable, with elevated troponin T (1241 ng/L) and NT-proBNP (2698 pg/mL). Initial investigations, including EKG and chest X-ray, were unremarkable with no thymoma. Left heart catheterization revealed severe multivessel coronary artery disease but no treatable lesions. He was noted to have fatigable ptosis and he subsequently developed bulbar symptoms, including hypophonia and dysphagia. A diagnosis of Myasthenia Gravis was suspected. Further evaluation showed respiratory muscle weakness (NIF -12 cm H2O, vital capacity 2L, mild hypercarbia on ABG) and progressive weakness, leading to intubation. Elevated creatine kinase (1527 U/L), persistent troponin elevation, and global hypokinesis on repeat echocardiography pointed to a likely diagnosis of myocarditis/myositis. Electromyography revealed neuropathy without acute findings, and serological testing for acetylcholine receptor antibodies, HMG-CoA reductase antibodies, and myositis was negative. ICI-induced MMM was diagnosed, and the patient was treated with methylprednisolone, IVIG, pyridostigmine, and ICI discontinuation. Despite plasmapheresis, his condition deteriorated. He developed septic shock from multiple infections (E-Coli bacteremia, Stenotrophomonas pneumonia) and progressed to cardiogenic shock, requiring vasopressors. Subsequent imaging revealed pneumoperitoneum concerning bowel perforation, but further diagnostic workup was declined by the family. Comfort care was initiated, and the patient passed away. Discussion: ICI use has grown rapidly, with agents like Nivolumab expanding treatment options for metastatic melanoma. However, MMM, a rare but severe complication, demands prompt recognition. Presentation often occurs within 21 days of ICI initiation, and patients may display elevated CPK and stable or rising troponin levels. Myasthenia gravis within MMM can cause rapid respiratory failure, with significant morbidity. Management includes corticosteroids, IVIG and immediate ICI discontinuation. Treatment should begin without waiting for confirmatory tests, given the syndrome's high mortality. Early, multidisciplinary intervention is essential in managing this fatal condition effectively.
A Rare Presentation of Triple M Syndrome From Pembrolizumab
Sahota, Raguwinder , Sahota, R.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7530-A7530

10.1164/ajrccm.2025.211.abstracts.a7530 Get It

Abstract Immune checkpoint inhibitors (ICIs) work by blocking inhibitory signals that normally restrain the immune system, allowing it to attack cancer cells. However, ICIs can sometimes lead to cross-reactivity, causing the immune system to mistakenly target the body's tissues, including muscle, resulting in myositis. Overactive T cells can attack muscle tissue, while ICIs may also promote autoantibody production, potentially leading to conditions like myasthenia gravis. In rare cases, mitochondrial function is affected, causing further muscle damage. Here, we present a unique case of ICI toxicity resulting in multiple organ damage, known as Triple M syndrome, encompassing myositis, myocarditis, and myasthenia gravis A 67-year-old female with a history of stage IIIA BRAF V600+ melanoma presented with myocarditis, myositis, and myasthenia, all associated with pembrolizumab treatment. Initial management included high-dose steroids, IVIG for suspected myasthenia gravis, and abatacept. Laboratory evaluation showed a creatine kinase (CK) of 14,925 and troponin of 8,427. Cardiac MRI confirmed myocarditis. She developed ventricular arrhythmias requiring Impella support and progressive conduction abnormalities necessitating a leadless pacemaker. Her respiratory status further declined with marked respiratory muscle weakness, consistent with both myasthenia gravis and myositis eventually requiring intubation. EMG studies showed defects in neuromuscular transmission. She underwent plasmapheresis and was started on pyridostigmine. Due to refractory symptoms, she was started on rituximab and eventually initiated sirolimus, mycophenolate, and basiliximab to address worsening immune-mediated toxicities. This case highlights a rare and severe presentation of immune checkpoint inhibitor (ICI)-induced toxicity resulting in Triple M syndrome, characterized by concurrent myocarditis, myositis, and myasthenia gravis. While ICIs are pivotal in activating the immune system to target malignancies, they can also lead to serious immune-related adverse events (irAEs) due to cross-reactivity with healthy tissue. Triple M syndrome is an uncommon but life-threatening complication involving multiple organ systems, which requires rapid recognition and intensive management. Myocarditis is a well-recognized yet infrequent irAE associated with ICIs, with a high mortality rate, especially when presenting alongside myositis and myasthenia gravis. Myasthenia gravis and myositis are believed to occur due to ICI-induced cross-reactivity of T cells and autoantibody formation. Management of severe irAEs, especially in cases involving multiple systems, remains challenging. This case underscores the necessity of a multidisciplinary approach to address overlapping toxicities and prevent further complications. The use of advanced immunosuppression, including sirolimus, mycophenolate, and basiliximab, reflects the need for targeted inhibition of the immune system when corticosteroids alone are insufficient.
In vivo human gracilis muscle active force‐length relationship is explained by the sliding filament theory
Wang, Zheng , Persad, Lomas S. , Binder‐Markey, Benjamin I. , Hoffman, E. Matthew , Litchy, William J. , Lieber, Richard L. , Hoffman, Ernest Matthew , Lieber, Richard L , Shin, Alexander Y. , Kaufman, Kenton R.

The Journal of Physiology | May 11, 2025 | Volume: 603 | Issue: 10 | Pages: 3049-3059

10.1113/jp288322 | PMID 40349312 Get It

AbstractThe sliding filament theory explains skeletal muscle fibre force change as a function of length based on the overlap of actin and myosin filaments. Although this length‐tension (LT) relationship has been well investigated in animal models, it is not known whether this microscopic sarcomere LT property can be scaled up five orders of magnitude to explain the LT behaviour of a long human muscle such as the gracilis. The goal of this study is to validate the sarcomere LT curve in humans based on human filament length combined with in vivo experimental data. Intraoperative measurements of maximal tetanic force and muscle‐tendon unit length at four different joint configurations (JC) were obtained from 19 patients undergoing free functioning muscle transfer surgery. With physiologically measured fibre length and estimated sarcomere shortening resulting from tendon compliance, we show that 79.7% variance in isometric force data is explained by a simple human sarcomere LT model. This study demonstrates that the human whole muscle LT relationship can be modelled by the sliding filament theory given patient‐specific fibre length, filament length, tendon compliance and sarcomere shortening. imageKey points Whole human gracilis muscle isometric length‐tension relationships were measured in the operating room. Grouped whole muscle raw length‐tension curves showed no obvious form. The width of each experimental length‐tension curve was highly variable across subjects and used to predict fibre length (serial sarcomere number). After whole muscle length‐tension curves were normalized to each patient's serial sarcomere number, the whole human muscle length‐tension curve was well predicted by the sliding filament theory.
Does a Mediastinal Mass Mandate Biopsy? A Case of Esophageal Duplication Cyst ( Atypical Case of Posterior Mediastinal Mass)
Rojas, Carlos A. , Azadeh, Natalya , Azar, Jimmy C. , Chen, Jun , Reeve, M., Azar, J.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7522-A7522

10.1164/ajrccm.2025.211.abstracts.a7522 Get It

Abstract Introduction Mediastinal masses may exhibit various clinical and pathological features. Posterior mediastinal lesions are often neurogenic, followed by lymphadenopathy, extramedullary hematopoiesis, paraspinal abscess, and rarely, foregut duplication cysts (prevalence: 0.122%). Given the rarity and diagnostic challenges, these masses are often biopsied, though may not be ideal. We present a case of esophageal duplication cyst (EDC). Case presentation A 33-year-old woman with mild intermittent asthma, had initially presented to an outside facility for chronic productive cough, episodic chest tightness and dyspnea both at rest and with exertion, inspiratory and expiratory wheezes. Despite multiple courses of prednisone for presumed asthma exacerbation, her symptoms persisted. An initial Computer Tomography (CT) Chest demonstrated a 5 x 4 x 3 cm mass within the visceral mediastinum. Bronchoscopy with endobronchial ultrasound and transbronchial needle aspiration of the mediastinal lymph nodes was nondiagnostic, showing scant lymphocytes and abundant mucin. Broad autoimmune, connective tissue disease, and infectious disease workups were negative, prompting referral to our facility. Physical exam and labs were unremarkable and pulmonary function testing showed no evidence of small airway obstruction. A High-Resolution CT Chest revealed a 3.1 x 3.7 x 4.5 cm noncalcified, well-circumscribed mass soft tissue density, adjacent to the esophagus with elevated Hounsfield units close to esophagus. Ultimately duplication cyst was suspected and Magnetic Resonance Imaging (MRI) with contrast showed high T1 and T2 signal within the lesion and no enhancement after contrast, deemed compatible with proteinaceous/hemorrhagic cyst (Figure 1 A-D). Biopsy was deferred given diagnostic MRI characteristics, and risk of secondary infection. The diagnosis of EDC was confirmed via multidisciplinary thoracic tumor board revision. Ultimately, she was referred for surgical resection. Discussion The incidence of EDC is 1 in 8,200, with a two-fold male prevalence over women. These patients may present with dysphagia, cough, stridor, pain, or arrhythmia since childhood, or may be entirely asymptomatic. EDCs can develop along the esophagus, with 90% lacking communication with the esophageal lumen. Although posterior mediastinal mass typically require biopsy to exclude malignancy, tissue biopsy should be avoided in cases with suspected duplication cyst given risk of infection, abscess formation and mediastinitis. Transesophageal endoscopic ultrasonography could further characterize the cyst, however MRI is considered the gold standard diagnostic modality. Conclusion MRI is the gold standard diagnostic modality of EDC. Biopsy should be avoided given the risk of infection. Clinicians should consider a broad differential for posterior mediastinal mass and avoid unnecessary invasive testing.